tradingkey.logo

STAAR Surgical Co

STAA
查看詳細走勢圖
23.350USD
-0.280-1.18%
收盤 12/26, 16:00美東報價延遲15分鐘
1.15B總市值
虧損本益比TTM

STAAR Surgical Co

23.350
-0.280-1.18%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.18%

5天

-7.12%

1月

-10.30%

6月

+38.74%

今年開始到現在

-3.87%

1年

-5.08%

查看詳細走勢圖

TradingKey STAAR Surgical Co股票評分

單位: USD 更新時間: 2025-12-26

操作建議

STAAR Surgical Co當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名52/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價24.97。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

STAAR Surgical Co評分

相關信息

行業排名
52 / 207
全市場排名
154 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
持有
評級
24.969
目標均價
+6.07%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

STAAR Surgical Co亮點

亮點風險
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-11.96,處於3年歷史低位
機構減倉
最新機構持股49.83M股,環比減少23.09%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉4.26M股
活躍度增加
近期活躍度增加,過去20天平均換手率2.61

STAAR Surgical Co新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

STAAR Surgical Co簡介

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
公司代碼STAA
公司STAAR Surgical Co
CEOFarrell (Stephen C)
網址https://www.staar.com/

常見問題

STAAR Surgical Co(STAA)的當前股價是多少?

STAAR Surgical Co(STAA)的當前股價是 23.350。

STAAR Surgical Co 的股票代碼是什麼?

STAAR Surgical Co的股票代碼是STAA。

STAAR Surgical Co股票的52週最高點是多少?

STAAR Surgical Co股票的52週最高點是30.810。

STAAR Surgical Co股票的52週最低點是多少?

STAAR Surgical Co股票的52週最低點是13.500。

STAAR Surgical Co的市值是多少?

STAAR Surgical Co的市值是1.15B。

STAAR Surgical Co的淨利潤是多少?

STAAR Surgical Co的淨利潤為-20.21M。

現在STAAR Surgical Co(STAA)的股票是買入、持有還是賣出?

根據分析師評級,STAAR Surgical Co(STAA)的總體評級為持有,目標價格為24.969。

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是多少

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是-1.952。
KeyAI